Literature DB >> 19728081

Genetic contribution of GADD45A to susceptibility to sporadic and non-BRCA1/2 familial breast cancers: a systematic evaluation in Chinese populations.

Ke-Da Yu1, Gen-Hong Di, Wen-Feng Li, Nan-Yan Rao, Lei Fan, Wen-Tao Yuan, Zhen Hu, Jiong Wu, Zhen-Zhou Shen, Wei Huang, Zhi-Ming Shao.   

Abstract

Growth arrest and DNA damage-induced 45, alpha (GADD45A) is a candidate breast cancer susceptibility gene because its product participates in DNA repair and it is a downstream gene of p53 and BRCA1, both of which are breast cancer susceptibility genes. We screened germline mutations of GADD45A in 185 non-BRCA1/2 familial breast cancer patients, but no deleterious mutation was found. Seven single-nucleotide-polymorphisms were identified in a subsample. Five common variants (minor allele frequency > 10%) were genotyped for association analyses to scrutinize the relationship between breast cancer and polymorphisms in GADD45A in two independent population sets (total n = 1,861). In the first case-control study (n = 1,457, cases 820, controls 637), a comparison of genotype frequencies between sporadic breast cancer patients and controls indicated the CT/TT-genotypes of +1506C>T and CG/CC-genotypes of +3204G>C were associated with decreased breast cancer risk (adjusted odds ratio (OR), 0.77; 95% confidence interval (CI), 0.62-0.96; and adjusted OR, 0.71; 95%CI, 0.57-0.88, respectively) compared with their wild-type homozygotes. A common haplotype CGTCC was also associated with reduced risk (P = 1.0 x 10(-4)). In a second familial breast cancer patient-based case-control study (n = 404, cases 185, controls 219), although +1506C>T and +3204G>C failed to be validated, the haplotype CGTCC showed a borderline significance. Notably, the combined P-values were robust for +3204G>C (P = 3.1 x 10(-4)) and CGTCC (P = 1.6 x 10(-5)). Moreover, CGTCC was correlated with a higher GADD45A expression in normal breast tissues. In conclusion, although germline mutations of GADD45A is not common in familial breast cancer patients, polymorphisms/haplotypes in GADD45A contribute to breast cancer risk, at least to sporadic breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19728081     DOI: 10.1007/s10549-009-0516-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  CYP1A1 is overexpressed upon incubation of breast cancer cells with a polyphenolic cocoa extract.

Authors:  Carlota Oleaga; Miriam García; Anna Solé; Carlos J Ciudad; Maria Izquierdo-Pulido; Véronique Noé
Journal:  Eur J Nutr       Date:  2011-08-06       Impact factor: 5.614

Review 2.  Roles for GADD45 in Development and Cancer.

Authors:  Kishan Patel; Mary Grace Murray; Kelly A Whelan
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Anticancer bioactive peptide (ACBP) inhibits gastric cancer cells by upregulating growth arrest and DNA damage-inducible gene 45A (GADD45A).

Authors:  Li-Ya Su; Hong-Yi Xin; Yong-Lei Liu; Jia-Ling Zhang; Hong-Wu Xin; Xiu-Lan Su
Journal:  Tumour Biol       Date:  2014-10

Review 4.  Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis.

Authors:  Sylwia Pietrasik; Gabriela Zajac; Jan Morawiec; Miroslaw Soszynski; Michal Fila; Janusz Blasiak
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

Review 5.  Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population.

Authors:  Lu Shen; Shizhen Zhang; Kaiyue Wang; Xiaochen Wang
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

Review 6.  Multifunctions of CRIF1 in cancers and mitochondrial dysfunction.

Authors:  Yangzhou Jiang; Yang Xiang; Chuanchuan Lin; Weiwei Zhang; Zhenxing Yang; Lixin Xiang; Yanni Xiao; Li Chen; Qian Ran; Zhongjun Li
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.